DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Marksans Pharma Limited — Press Release

NSE 1 hr ago·12 Aug 2026, 7:04 am

Marksans Pharma

Marksans Pharma has announced its unaudited financial results for the quarter that ended on June 30, 2026. The company has submitted a formal press release to the stock exchanges to disclose these figures, which are subject to audit.

For investors, this update provides a crucial snapshot of the company's operational performance and financial health during the first half of the fiscal year. It highlights key metrics such as revenue growth, profit margins, and cash flow, which are essential for assessing the company's current trajectory and future potential.

Investors should monitor the detailed financial statements for insights into the company's strategic direction. Watch for commentary on market conditions, product performance, and any guidance provided by management regarding upcoming quarters.